Reading CRL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRL free→Reading CRL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRL free→QuarterlyIQ Insights · CRL
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 5, 2026, Charles River Laboratories International, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). As further discussed below, at the Annual Meeting, the shareholders of the Company approved the Company’s 2026 Long-Term Incentive Plan (the “2026 Incentive Plan”). The Board of Directors of the Company…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On May 7, 2026, Charles River Laboratories International, Inc. issued a press release providing financial re…
Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Planned Divestiture of CDMO and Cell Solutions Businesses On February 25, 2026, Charles River Laboratories International, Inc. (t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer. Mr. Coleman will join the company with a tentative start date of April 6, 2026. Mr. Coleman, 58, will join Charles River with over 30 years of strong financial and operational management experience, inc…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On February 18, 2026, Charles River Laboratories International, Inc. issued a press release providing financ…
Regulation FD Disclosure The Slide Presentation prepared in connection with the J.P. Morgan Conference also includes the following statements as to recent client demand trends and preliminary 2026 outlook: • Q4 DSA Trends: DSA demand trends continued to improve throughout the second half of 2025, resulting in preliminary DSA net book-to-bill of approximately 1.1x in the fourth quarter of 2025 – Improving trends during the second half of 2025 were primarily driven by small and mid-sized biotec…
above shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. This Current Report on 8-K contains a forward-looking, non-GAAP financial measure: non-GAAP e…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Chief Executive Officer Transition On January 8, 2026, the Board of Directors (the “Board”) of Charles River Laboratories International, Inc. (the “Company”) announced a leadership transition plan. Mr. James C. Foster, our current Chairman of the Board, President and Chief Executive Officer, intends to step down as Chief Executive Officer and Chairm…
Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. (“Charles River”, the “Company”, or the “Registrant”) is presenting at the Evercor…
Other Events As previously disclosed, on May 16, 2023, Charles River Laboratories International, Inc., (Company) received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures. In addition, the Company’s Audit Committee retained counsel to conduct an in…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On November 5, 2025, Charles River Laboratories International, Inc. issued a press release providing financi…
to report the resignation of Flavia H. Pease as Corporate Executive Vice President, Chief Financial Officer of the Company and the appointment of Michael G. Knell as interim Chief Financial Officer of the Company. The Company is filing this Form 8-K/A to disclose details of Mr. Knell’s compensation that were not determined at the time of the original filing. On September 15, 2025, in connection with Mr. Knell’s appointment as interim Chief Financial Officer and interim principal financial off…
Regulation FD Disclosure On September 16, 2025, the Company issued a press release announcing Ms. Pease’s departure and Mr. Knell’s appointment. A copy of the press release is attached as Exhibit 99.1 hereto. The press release, attached as an exhibit to this report, includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the press release are "forward-looking" rather than historic. The press…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On September 12, 2025, Flavia H. Pease informed Charles River Laboratories International, Inc. (the “Company”) of her intention to resign from her position as the Company’s Corporate Executive Vice President, Chief Financial Officer effective on September 29, 2025. Ms. Pease’s decision to resign her position is not the result of any disagreemen…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On August 6, 2025, Charles River Laboratories International, Inc. issued a press release providing financial…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 20, 2025, Charles River Laboratories International, Inc. (the “Company”) and Mr. James C. Foster, Chair, President and Chief Executive Officer of the Company, entered into, and the Board approved, Amendment No. 1 (the “Foster Amendment”) to Mr. Foster’s Amended and Restated Employment Agreement with the Company, dated as of May 18, 2021 (the…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 5.02(b) On May 6, 2025, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman each notified the Company of his or her decision to not stand for re-election to the Board at the 2025 Annual Meeting following the expiration of their respective terms prior to the 2025 Annual Meeting (resulting in four vacancies on the Boa…
Entry into a Material Definitive Agreement. On May 6, 2025 (the “Effective Date”), Charles River Laboratories International, Inc. (the “Company”) entered into a Cooperation Agreement (the “Cooperation Agreement”) by and among Elliott Investment Management L.P., a Delaware limited partnership, Elliott Associates, L.P., a Delaware limited partnership and Elliott International, L.P., a Cayman Islands limited partnership (each, an “Elliott Party,” and collectively, the “Elliott Parties”). Pursuan…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On May 7, 2025, Charles River Laboratories International, Inc. issued a press release providing financial re…
Other Events Purchase of Shares of Company Common Stock On February 20, 2025: • Mr. James C. Foster, Chair, President and Chief Executive Officer of Charles River Laboratories International, Inc. (the “Company”) purchased 6,075 shares of the Company’s common stock at an average price of $165.01 for an aggregate purchase price of approximately $1 million in open market transactions. • Ms. Birgit Girshick, Corporate Executive Vice President and Chief Operating Officer of the Company purchased 1…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On February 19, 2025, Charles River Laboratories International, Inc. issued a press release providing financ…
Regulation FD Disclosure The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Charles River Laboratories International, Inc. ("Charles River", the "Company", or the “Registrant”) will be presenting at the 43…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On December 13, 2024, Charles River Laboratories International, Inc. (“Charles River”) amended and restated its existing credit agreement with certain financial institutions and JPMorgan Chase Bank, N.A., as administrative agent (the “Tenth Amended and Restated Credit Agreement”). The Tenth Amended and Restated Credit Agreement (1) extends the maturity date for the facilities, (2…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On November 6, 2024, Charles River Laboratories International, Inc. issued a press release providing financi…
Results of Operations and Financial Condition The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On August 7, 2024, Charles River Laboratories International, Inc. issued a press release providing financial…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.